Silibinin
Small moleculeexperimental
Chlordiazepoxide hydrochloride, sold under the brand name Librium is a sedative and hypnotic medication of the benzodiazepine class. It is used to treat anxiety, insomnia and symptoms of withdrawal from alcohol, benzodiazepines, and other drugs. It is also used to discontinue long term use of other, shorter acting benzodiazepines due to its long half-life. — Wikipedia
Clinical trial activity
27 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
12
Phase 3
5
Phase 4
2
Earliest trial started Aug 1, 2006 (NCT00487721)
Timeline
Indications
Approved for
Studied for
- Acute-On-Chronic Liver Failure · Phase 4
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Depression · Phase 3
- Diabetic Nephropathies · Phase 2
- Healthy Volunteers · Phase 1
- Hepatitis C · Phase 2
- Hepatitis C, Chronic · Phase 2/Phase 3
- HIV · Phase 2
- Hypertension · Phase 4
- Ischemic Stroke · Phase 2
- Liver Cirrhosis · Phase 3
- Liver Failure · Phase 3
- Mushroom Poisoning · Phase 2/Phase 3
- Oxidative Stress · Phase 2
- Prostatic Neoplasms · Phase 2
- Proteinuria · Phase 2
- Smoking · Phase 1
- Work · Phase 3
Mechanism of action
- Cell membraneSTABILISER
Cell membrane stabiliser
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C2Oc3cc(C4Oc5cc(O)cc(O)c5C(=O)C4O)ccc3OC2CO)ccc1O- Mol. weight
- 482.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChlordiazepoxide ↗
- ChEMBLCHEMBL1401508 ↗
- WikipediaSilibinin ↗
Also known as
- 2,3-dehydrosilybin
- alepa-forte
- ardeyhepan
- cdp
- cefasilymarin
- durasilymarin
- hepabesch
- hepa-loges
- hepa-merz sil
- hepar-pasc
- heparsyx
- hepatos
- heplant
- lagosa
- legalon forte
- silibin
- silibin
- silibin
- silibinin
- silibinin
- silibinin
- silibinin
- silibrin
- silibrin
- silybin
- silybin
- silybin
- silybinin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06964815 | N/A | Oct 31, 2025 | Istituto Oncologico Veneto IRCCS |
| NCT07024966 | N/A | Aug 1, 2025 | Circe, S.L., Eurecat |
| NCT05689619 | N/A | Sep 1, 2023 | University of Turin |
| NCT05793489 | N/A | Mar 6, 2023 | Istituto Clinico Humanitas - Rozzano (MI), Italy |
| NCT05497765 | N/A | Aug 1, 2022 | Guangdong Medical University, Guangzhou Medical University |
| NCT05069298 | N/A | Jan 31, 2022 | Universidad Católica San Antonio de Murcia |
| NCT04649593 | N/A | Jan 1, 2020 | Karolinska Institute |
| NCT04028518 | Phase 2 | Jul 20, 2019 | Angde Biotech Pharmaceutical Co., Ltd., Capital Medical University |
| NCT03687073 | Phase 1 | Nov 30, 2018 | University of Minnesota |
| NCT03650972 | N/A | Sep 15, 2018 | University of Turku |
| NCT03216668 | Phase 3 | Jun 15, 2017 | Nhat Nhat Pharmaceutical Company |
| NCT02146118 | Phase 2 | Apr 1, 2014 | Kosin University, MedicalLogic |
| NCT03538327 | Phase 4 | Oct 31, 2013 | Magna Graecia University |
| NCT02633696 | Phase 1 | Oct 1, 2013 | Universidad Complutense de Madrid |
| NCT01871662 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2013 | Cairo University, Rottapharm, University of Maryland |
| NCT01816490 | Phase 2 | Apr 1, 2013 | University of Zurich |
| NCT02347319 | Phase 4 | Apr 1, 2012 | PharmaKing |
| NCT01518933 | Phase 2 | Aug 1, 2011 | Azienda Ospedaliera Universitaria Policlinico, Rottapharm, University of Bari |
| NCT01265563 | Phase 2 | Jan 1, 2011 | Department of Veteran Affairs, National Center for Complementary and Integrative Health (NCCIH), South Texas Health Care System, San Antonio, TX |
| NCT01535092 | Phase 2 | Sep 1, 2010 | Rottapharm, University of Barcelona |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (40)
40 organizations
Page 1 / 2